DIM — Sartorius Stedim Biotech SA Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapHigh Flyer

Annual income statement for Sartorius Stedim Biotech SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.

	R2020 December 31st	2021 December 31st	2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,910	2,887	3,493	2,776	2,780
Cost of Revenue
Gross Profit	1,003	1,553	1,835	1,234	1,207
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,438	2,022	2,498	2,326	2,420
Operating Profit	472	865	995	449	360
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	461	647	1,130	402	219
Provision for Income Taxes
Net Income After Taxes	339	414	880	313	179
Minority Interest
Net Income Before Extraordinary Items
Net Income	336	414	876	310	175
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	336	414	876	310	175
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	3.9	4.68	9.9	4.33	3.07
Dividends per Share